Table 1

Patient characteristics

Placebo (n = 38)Low-dose aliretinoin (n = 38)High-dose aliretinoin (n = 38)P
Age (years)
 Mean ± SD26.5 ± 6.425.6 ± 5.727.1 ± 5.9NS
 Median (range)24.5 (18–40)24.5 (18–39)26 (18–41)
Race
 Caucasian68%68%74%NS
 African-American29%29%26%
 Other2%3%0%
Weight (lbs.)
 Mean ± SD151.8 ± 35.5147.5 ± 40166.2 ± 44.7NS
 Median (range)146 (96–236)136 (86–234)160 (104–277)
Height (inches)
 Mean ± SD63.9 ± 2.764.9 ± 2.664.5 ± 2.6NS
 Median (range)64 (56–68)65 (58–71)65 (59–71)
Pretreatment biopsy (all patients enrolled)
 CIN 215 (39%)21 (55%)9 (24%)0.019
 CIN 323 (61%)17 (45%)29 (76%)
Pretreatment biopsy (all patients included in efficacy analysis)
 CIN 215 (41%)18 (53%)8 (24%)0.055
 CIN 322 (59%)16 (47%)25 (76%)